Peer Review reports
From: A new indolocarbazole derivative in melanoma and carcinoma lung in vivo treatment
Original Submission | ||
---|---|---|
11 Feb 2021 | Submitted | Original manuscript |
Resubmission - Version 2 | ||
Submitted | Manuscript version 2 | |
Resubmission - Version 3 | ||
Submitted | Manuscript version 3 | |
21 Feb 2021 | Reviewed | Reviewer Report |
2 Mar 2021 | Reviewed | Reviewer Report |
24 Mar 2021 | Author responded | Author comments - Lyudmila Nikolaeva |
Resubmission - Version 4 | ||
24 Mar 2021 | Submitted | Manuscript version 4 |
24 Mar 2021 | Author responded | Author comments - Lyudmila Nikolaeva |
Resubmission - Version 5 | ||
24 Mar 2021 | Submitted | Manuscript version 5 |
25 Mar 2021 | Reviewed | Reviewer Report |
30 Mar 2021 | Reviewed | Reviewer Report |
Resubmission - Version 6 | ||
Submitted | Manuscript version 6 | |
Publishing | ||
31 Mar 2021 | Editorially accepted | |
10 Apr 2021 | Article published | 10.1186/s12906-021-03294-2 |
You can find further information about peer review here.